Locations:
Search IconSearch
January 23, 2023/Cancer

Research Shows Link Between Antibiotic Use and Ovarian Cancer Outcomes

Reassessing antibiotic dosage and type and restoring gut biome could improve survival rates

Ovarian tumor

Antibiotics routinely used for ovarian cancer patients indiscriminately kill gut bacteria, leading to faster cancer progression and lower survival rates, according to a retrospective clinical analysis of patients conducted by Cleveland Clinic research.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The results, published in Cancer Research, challenge the standard of care for epithelial ovarian cancer (EOC), the leading cause of gynecologic cancer death. Although most ovarian cancer patients respond to chemotherapy, tumors recur in more than 80% of patients, leading to a survival rate of less than five years.

Antibiotics are crucial to treating bacterial infections during chemotherapy, but they kill bacteria that is essential for patients with ovarian cancer to respond to treatment. Selecting antibiotics or dosages proven to preserve more of the microbiome could preserve the balance of gut bacteria and prevent tumor progression or treatment resistance, says Ofer Reizes, PhD, Department of Cardiovascular & Metabolic Sciences at Cleveland Clinic and lead investigator on the study.

Built on earlier research, study focuses on gut microbiome

The research digs deeper into an earlier study of women with advanced EOC undergoing platinum chemotherapy, which was published by Cleveland Clinic Ob/Gyn and Women’s Health Institute in Gynecological Oncology.The findings of this study indicate that antibiotic treatment was associated with decreased progression-free survival and overall survival.

Dr. Reizes’ investigative team, including members of the Center for Microbiome and Human Health, Taussig Cancer Center and the Women’s Health Institute, focused its research on the gut microbiome and performed additional studies to show that reintroducing healthy bacteria into the gut is sufficient to slow down ovarian cancer growth and restore tumor sensitivity to chemotherapy.

Advertisement

Looking at this problem through the microbiome can help explain why some patients are initially resistant to chemotherapy, as well as guide the use of antibiotics in clinical practice, says Chad Michener, MD, Vice Chair for Ob/Gyn & Women’s Health Institute. Physicians need to be good stewards for antibiotics use, he says, and this study provides further evidence to support selecting targeted, short-term antibiotics to treat infections and considering when antibiotics for prophylaxis are necessary.

Potential for metabolites to restore balance

The study also serves as a starting point for research on how to most effectively rebuild gut colonies. Some patients might benefit from reintroduction of bacteria through procedures like fecal microbial transplantation, while others could rebalance their gut through specific types of probiotics or dietary changes.

“Maybe it’s as simple as giving probiotics when people have cleared their infection, but it may be more in-depth than that,” says Dr. Michener.

Dr. Reizes, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, says that the team is currently working on whether introducing specific metabolites produced by the bacteria, identified in the study, could be used to restore that balance. This study highlighted two potential metabolites that could play a role in sensitivity to treatment and suppressing tumor growth – Indole-3-propionic acid and indoxyl sulfate.

Advertisement

Related Articles

Dr. Elias
Q&A With Ovarian Cancer Physician Scientist Kevin Elias, MD

Robust research focuses on detection and prevention

Medical illustration of an ovarian tumor
Ultrasound During Pregnancy Reveals Ovarian Cancer

Case highlights range of options for treating malignancies in pregnancy

Woman exercising
July 3, 2024/Cancer/Patient Support
Prehabilitation Program Aims to Improve Outcomes for Older Patients with Ovarian or Pancreatic Cancer

Clinical trial to assess the value of nutritional, physical therapy and social supports prior to preoperative chemotherapy

antibiotic pills in blister packs
Myasthenia Gravis Exacerbation With Quinolone and Macrolide Antibiotics: What Is the Risk?

Retrospective analysis assesses frequency and severity relative to a reference antibiotic

Ovarian tumor
Adoptive Immunotherapy is Being Studied in Ovarian Cancer

Trial examines novel approach for a disease with a high mortality rate

UTI bacteria and artificial intelligence
AI Algorithms Accurately Predict Antibiotic Resistance in UTI

Up to 3 days faster than waiting for urine culture results

Cervical cancer cells
Fertility-Sparing Management of Early-Stage Cervical Cancer

Studying trends of conization with lymph node evaluation, trachelectomy and radical hysterectomy

BRCA1
February 28, 2023/Cancer
Optimizing Care for Those With Genetic Predisposition to Ovarian and Breast Cancer

A well-prepared team meets the distinctive needs of patients at hereditary high risk

Ad